{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T03:40:04Z","timestamp":1751859604169,"version":"3.41.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41409-025-02607-0","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T17:52:56Z","timestamp":1744912376000},"page":"1057-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma: a real-world experience"],"prefix":"10.1038","volume":"60","author":[{"given":"Bhavesh","family":"Mohan Lal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-5964","authenticated-orcid":false,"given":"Toshali","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marah","family":"Alzubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawad","family":"Alrawabdeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"John","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-6612","authenticated-orcid":false,"given":"Eric R.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-1282","authenticated-orcid":false,"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2607_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/OTT.S370880","volume":"16","author":"T Shrivastava","year":"2023","unstructured":"Shrivastava T, Van Rhee F, Al Hadidi S. Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives. Onco Targets Ther. 2023;16:441\u201364. https:\/\/doi.org\/10.2147\/OTT.S370880.","journal-title":"Onco Targets Ther"},{"key":"2607_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl J Med. 2021;384:705\u201316.","journal-title":"N. Engl J Med"},{"key":"2607_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol J Am Soc Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2607_CR4","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol J Am Soc Clin Oncol. 2023;41:2087\u201397.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2607_CR5","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjh.19505","volume":"205","author":"B Ferment","year":"2024","unstructured":"Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, et al. French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry. Br J Haematol. 2024;205:990\u20138. https:\/\/doi.org\/10.1111\/bjh.19505.","journal-title":"Br J Haematol"},{"key":"2607_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41409-022-01905-1","volume":"58","author":"S Al Hadidi","year":"2023","unstructured":"Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, et al. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023;58:443\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"2607_CR7","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.23.00226","volume":"41","author":"R Chakraborty","year":"2023","unstructured":"Chakraborty R, Al Hadidi S. Intent matters: real-world applicability of idecabtagene vicleucel usage in the United States. J Clin Oncol. 2023;41:3657\u20138.","journal-title":"J Clin Oncol"},{"key":"2607_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"2607_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"2607_CR10","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.2022016170","volume":"140","author":"B Paiva","year":"2022","unstructured":"Paiva B, San-Miguel J, Avet-Loiseau H. MRD in multiple myeloma: does CR really matter? Blood. 2022;140:2423\u20138.","journal-title":"Blood"},{"key":"2607_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141:219\u201330.","journal-title":"Blood"},{"key":"2607_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00507-2","volume":"11","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, et al. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 2021;11:116.","journal-title":"Blood Cancer J"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02607-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02607-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02607-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T03:05:55Z","timestamp":1751857555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02607-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2607"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02607-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SAH reports receiving consulting fees from Jansen and Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}